LONDON (Reuters) – GlaxoSmithKline, Britain's largest drugmaker, renewed its promise to return to development this year, following failing to deliver a hoped-for sales plus margin healing inside 2012. GSK moreover announced a restructuring of European operations, drug production plus analysis, crafted to conserve at smallest 1 billion pounds ($ 1.6 billion) yearly by 2016, whilst it placed its Lucozade plus Ribena refreshments brands beneath strategic review. After placing a quantity of main drug patent losses behind it, GSK had initially banked about pulling from its trough inside 2012. …
There are no comments yet. Why not be the first to speak your mind.